Traumatic brain injury (TBI) is the leading cause of death and disability in young adults in the
developed world. The accuracy of early outcome-prediction remains poor even when all …

Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in
previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess …

Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …

Cerebral metabolism is tightly regulated and fundamental for healthy neurological function.
There is increasing evidence that alterations in this metabolism may be a precursor and …

Abstract From 1991–2002, we treated 58 patients with multiple sclerosis (MS) using the
humanised monoclonal antibody, Campath–1H, which causes prolonged T lymphocyte …

The elective treatment of patients with multiple sclerosis, using a humanized anti‐leukocyte
(CD52) monoclonal antibody (Campath‐1H), has illuminated mechanisms that underlie the …

Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and
then no further therapy is required for 12 months. It causes rapid and prolonged lymphocyte …

Background Multiple sclerosis results from T-cell-dependent inflammatory demyelination of
the central nervous system. Our objective was long-term suppression of inflammation with …

Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal
antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing …

Following lymphocyte depletion, homeostatic mechanisms drive the reconstitution of
lymphocytes. We prospectively studied this process in 16 patients for 1 year after a single …